<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yu FC</submitter><funding>Reserve Talent Foundation of Yunnan Province for Middle-aged and Young Academic and Technical Leaders</funding><funding>Ministry of Education of the People&amp;apos;s Republic of China</funding><funding>National Natural Science Foundation of China</funding><pagination>873-889</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6044579</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2(3)</volume><pubmed_abstract>Self-labeled inhibitors (SLIs) are promising for creating links, ranging from cancer therapy and metastatic pathways to mechanistic elucidation. In this study, a new category of "two-in-one" fluorescent xanthone inhibitors was developed for the systematic evaluation of anticancer activity and the selective imaging of cytoplasm in vitro. These xanthone inhibitors presented high fluorescent brightness, working over a wide pH range enabled by a "switchable reaction" of the heterocyclic backbone. The strength and nature of fluorescence were probed via spectroscopic methods and density functional theory calculations on the molecular level, respectively. Along with the potent anticancer activity, which was demonstrated using MTT and clonogenic assays with high fluorescent brightness in the cytop</pubmed_abstract><journal>ACS omega</journal><pubmed_title>Beyond the Antagonism: Self-Labeled Xanthone Inhibitors as Modeled "Two-in-One" Drugs in Cancer Therapy.</pubmed_title><pmcid>PMC6044579</pmcid><funding_grant_id>21262042</funding_grant_id><funding_grant_id>81260501</funding_grant_id><funding_grant_id>2012HB001</funding_grant_id><funding_grant_id>IRT13095</funding_grant_id><funding_grant_id>21662042</funding_grant_id><funding_grant_id>U1202221</funding_grant_id><funding_grant_id>21362042</funding_grant_id><pubmed_authors>Lin XR</pubmed_authors><pubmed_authors>Liu FF</pubmed_authors><pubmed_authors>Ma YL</pubmed_authors><pubmed_authors>Zhang JH</pubmed_authors><pubmed_authors>Qu WW</pubmed_authors><pubmed_authors>Yan SJ</pubmed_authors><pubmed_authors>Yu FC</pubmed_authors><pubmed_authors>Lin J</pubmed_authors><pubmed_authors>Liu ZC</pubmed_authors><pubmed_authors>Wu W</pubmed_authors></additional><is_claimable>false</is_claimable><name>Beyond the Antagonism: Self-Labeled Xanthone Inhibitors as Modeled "Two-in-One" Drugs in Cancer Therapy.</name><description>Self-labeled inhibitors (SLIs) are promising for creating links, ranging from cancer therapy and metastatic pathways to mechanistic elucidation. In this study, a new category of "two-in-one" fluorescent xanthone inhibitors was developed for the systematic evaluation of anticancer activity and the selective imaging of cytoplasm in vitro. These xanthone inhibitors presented high fluorescent brightness, working over a wide pH range enabled by a "switchable reaction" of the heterocyclic backbone. The strength and nature of fluorescence were probed via spectroscopic methods and density functional theory calculations on the molecular level, respectively. Along with the potent anticancer activity, which was demonstrated using MTT and clonogenic assays with high fluorescent brightness in the cytop</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Mar</publication><modification>2026-05-05T23:41:58.839Z</modification><creation>2025-05-29T20:27:32.298Z</creation></dates><accession>S-EPMC6044579</accession><cross_references><pubmed>30023617</pubmed><doi>10.1021/acsomega.6b00545</doi></cross_references></HashMap>